WO2001049301A1 - Methods of using electron active compounds for managing cancer - Google Patents
Methods of using electron active compounds for managing cancer Download PDFInfo
- Publication number
- WO2001049301A1 WO2001049301A1 PCT/US2000/029113 US0029113W WO0149301A1 WO 2001049301 A1 WO2001049301 A1 WO 2001049301A1 US 0029113 W US0029113 W US 0029113W WO 0149301 A1 WO0149301 A1 WO 0149301A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- metal oxide
- oxide compound
- iii
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/12—Face or body powders for grooming, adorning or absorbing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G3/00—Compounds of copper
- C01G3/02—Oxides; Hydroxides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to pharmaceutical compositions including at least one metal oxide, such as an electron active metal oxide, and methods of using such compositions, for the prevention, treatment, and management of cancer and conditions or diseases related to the presence of cancer or a predisposition to cancer.
- metal oxide such as an electron active metal oxide
- Cancers are a leading cause of death in animals and humans.
- the exact cause of cancer is not known, but links between certain factors, such as smoking or exposure to carcinogens including tobacco smoke and chromium (VI), exposure to radiation, such as from x-rays, radioisotopes, and ultra-violet light, viruses, such as papaloma, Espstem Barr, and Raus sarcoma virus and the incidence of certain types of cancers and tumors has been shown by a number of researchers. Genetic factors and genome defects such as those found a chromosome 11 have also been linked to cancer.
- Traditional methods of cancer therapy include treatment with chemotherapeutic agents that inhibit cell division or radiation therapy that disrupts DNA in dividing cells.
- breast carcinoma is the most common malignancy among women and shares with lung carcinoma the highest fatality rate of all cancers affecting females. For example, approximately one of every 11 women in the U.S.A. will develop breast cancer. For white women, the probability is about 1 in 10; for African American women, the rate is close to 1 in 14. The annual mortality rate from 1930 to the present has remained fairly constant at about 27 deaths per 1000,000 females, and is slightly higher for whites than African Americans.
- breast carcinoma is rare before age 30 but the incidence rises rapidly after menopause. Post-menopausal breast masses are typically considered cancerous until biopsy proves otherwise. Cystosarcoma phyllodes, which are a non-cancerous tumor, are the most common tumor of the breast; other malignancies are significantly more rare. Breast cancer in men is rare and tends not to be recognized until late with poor therapeutic results.
- Most breast cancers including those frequently designated as scirrhus, infiltrative, papillary, ductile, medullary, and lobular, appear as a slowly growing, painless mass, though a vague discomfort may be present.
- Physical signs typically include a retracted nipple, bleeding from the nipple, a distorted areola or breast contour, skin dimpling over the lesion, attachment of the mass to surrounding tissue, including the underlying fascia and overlying skin, edema of the skin of the breast with an orange peel appearance, and axillary or supraclavicular lymph nodes. In advanced cases, skin nodules with ultimate breakdown and ulcer formation may be seen.
- mice breast tumor virus vtmr
- Current treatments for breast cancer in general include surgery, radiotherapy, chemotherapy and hormonal therapy.
- Cervical cancer includes those cancer moieties which are indigenous to the cervix. These cancer moieties are referred to generally as cervical carcinomas of which 85 - 90% are squamous cell carcinomas, and the balance are largely adenocarcinomas. The severity of cervical cancers are gauged by the clinical tests called PAP smears which indicate whether the carcinoma cells are confined to the cervix or have penetrated beyond it but not to the pelvic wall, or to the pelvic wall itself and even beyond the pelvis. Cervical cancers kill about 33% of their victims annually in the United States.
- Carcinoma of the uterine cervix the second most common malignancy of the female reproductive tract, most commonly affects women aged 40 to 56 years old. The incidence is higher among women from lower socioeconomic groups and among those with a history of early and frequent coitus and multiple sexual partners.
- nsv-2 have been implicated as important in the etiology of cervical neoplasia.
- minimal cervical dysplasia in which abnormal cell proliferation occurs in the lower third of the epithelium. Most of the minimal dysplasias are self-limiting and regress to normal tissue. Most severe dysplasias in the upper two-thirds of the epithelium showing abnormal proliferation, however, progress to carcinoma in situ, in which a full thickness of the epithelium contains abnormal calls. When cancer cells penetrate the basement membrane and invade the stroma (invasive carcinoma) they can spread by direct extension to adjacent pelvic organs or by lymphatic permeation and dissemination.
- cervical carcinomas 85 to 90% are squamous cell carcinoma.
- cervical smears can detect 90%) of early cervical neoplasias.
- the use of cervical smears has reduced the death rate from cervical cancer by more than 50% through recognition and treatment of pre-invasive neoplasia.
- Treatment of cervical cancer typically involves conization, radiotherapy, surgical therapy, and chemotherapy.
- the results of cervical smear tests may be grouped into four categories: class I characterized by the absence of observed abnormal cells; class II characterized by the presence of atypical cells and usually associated with inflammation; class III characterized by the presence of cells representative of or suspicious of carcinoma; and classes IV and V each characterized by the presence of carcinoma cells.
- Stage 0 is characterized by carcinoma in situ with intra epithelial carcinoma.
- Stage I includes carcinomas strictly confined to the cervix.
- Stage LA is characterized by micro invasive carcinoma and stage LB is characterized by occult cancer.
- stage II the carcinoma extends beyond the cervix but not onto the pelvic wall.
- Stage IIA exhibits no obvious parametrial involvement while stage IIB exhibits obvious parametrial involvement.
- stage III the carcinoma extends onto the pelvic wall.
- Stage IIIA is characterized by the lack of extension onto the pelvic wall and stage IIIB is characterized by extension onto the pelvic wall.
- Stage IV the carcinoma has extended beyond the true pelvis or has clinically involved the mucosa of the bladder.
- Stage IVA is characterized by the spread of the growth to adjacent organs.
- Stage IVB is characterized by the spread to distant organs.
- Skin cancer is a disease in which cancer (malignant) cells are found in the layers of the skin.
- the skin has two main layers and several kinds of cells: a top layer called the epidermis, which contains three kinds of cells: flat, scaly cells on the surface called squamous cells; round cells called basal cells; and cells called melanocytes, which give the skin its color.
- the dermis is the inner, second layer of the skin.
- the skin is the most environmentally-stressed organ in mammals, particularly in humans.
- the skin is subjected to toxic chemicals and hostile environments, as well as being the only organ directly exposed to ultraviolet ("UV") light in the presence of oxygen. Lengthy exposure of the skin to UV light typically damages the skin, resulting, in sunburn, photo-aging, carcinogenesis, and other related skin disorders.
- UV ultraviolet
- "Skin cancer” is generally used to describe the three major forms of skin cancer; basal cell and squamous carcinoma together with melanoma. These carcinomas account for about 97% of skin cancers. Melanoma, however, accounts for over 87%o of deaths due to said cancers.
- Melanoma is a disease of the skin in which cancer (malignant) cells are associated with the cells that color the skin (melanocytes). Melanoma usually occurs in adults, but it may occasionally be found in children and adolescents. Melanoma is sometimes called cutaneous melanoma or malignant melanoma. Melanoma can spread (metastasize) quickly to other parts of the body through the lymph system or through the blood.
- non-melanoma skin cancer will be basal cell carcinoma. It can occur at any location on the body surface, but occurs more commonly on sun-exposed surfaces, such as the face. The earliest sign may be a red flat area, a small nodule, a small spot that bleeds on rubbing, a small ulcer, or a scaly patch. About 20%) of non-melanoma skin cancer will be squamous cell carcinoma. The difference between basal cell carcinoma and squamous cell carcinoma is often discernable only at the microscopic level, as the two may look identical. Squamous cell carcinoma, however, tends to grow more rapidly, and form an ulcer sooner. Squamous cell carcinoma may afflict any skin surface, but is common on the lips and ears.
- Neurofibromatosis is a hereditary autosomal dominant disorder that is accompanied by a predisposition to cancer. Neurofibromatosis produces pigmented spots and tumors of the skin and of peripheral, optic and acoustic nerves. Subcutaneous and bony deformities may also be observed. One third of the patients with neurofibromatosis are asymptomatic and the condition is discovered during routine examination. In one-third of patients, cosmetic problems are the initial complaints. Characteristic skin lesions, apparent at birth or in infancy in 90% of the patients, include medium brown patches distributed most commonly over the trunk, pelvis, and flexor creases of elbows and knees. For diagnostic purposes, the presence of six or more of these freckle-like lesions with one larger than 1.5 cm is characteristic of neurofibromatosis. Multiple cutaneous tumors, flesh colored and of variable size and shape typically appear in late childhood.
- compositions that can be administered at dosage levels low enough to insure survival of a cancer patient but which are sufficiently cytotoxic to cancer cells or cells associated with cancer to retard or eliminate continuing cell division after treatment, i.e., management or treatment of the cancer.
- Metal oxides such as electron active metal oxides comprising multivalent silver cations, have been disclosed for various uses, as they are reported to be non-toxic to animals and humans.
- M. Antelman "Anti-Pathogenic Multivalent Silver Molecular Semiconductors,” Precious Metals, vol. 16:141-149 (1992); M. Antelman, “Multivalent Silver Bactericides,” Precious Metals, vol. 16:151-163 (1992).
- tetrasilver tetroxide activated with an oxidizing agent is disclosed for use in bactericidal, fungicidal, and algicidal use, such as in municipal and industrial water treatment applications and for the treatment of ALDS.
- a variety of sources also report the use of certain divalent silver compounds for water treatment, as well as the use of such compounds, typically in combination with certain oxidizing agents, metals, or other compounds, as disinfectants, bactericides, algicides, and fungicides.
- One source also reports a single in vitro study of the use of such compounds for the treatment of ALDS.
- These sources include M. Antelman, "Silver (II, III) Disinfectants," Soap/Cosmetics/Chemical Specialties, pp. 52-59 (Mar., 1994), and U.S. Patent Nos. 5,017,295; 5,073,382; 5,078,902; 5,089,275; 5,098,582; 5,211,855; 5,223,149; 5,336,416; and 5,772,896.
- U.S. Patent No. 5,336,499 discloses tetrasilver tetroxide and persulfate compositions having certain in vitro anti-pathogenic properties, i.e., bactericidal, fungicidal, viricidal, and algicidal, in certain concentrations as low as 0.3 ppm, particularly in nutrient broth cultures.
- the persulfate is disclosed to be an oxidizing agent that activates the tetroxide crystals.
- U.S. Patent No. 5,571,520 discloses the use of molecular crystals of tetrasilver tetroxide, particularly with oxidizing agents to enhance the efficiency of such devices, for killing pathogenic microorganisms, such as staph infections. Amounts of 10 ppm sodium persulfate as an oxidizing agent were used with certain amounts of silver tetroxide in the reported in vitro testing. One human study involved in vivo curing of a gynecological yeast infection with 10 ppm of the silver tetroxide and 40 ppm sodium persulfate.
- U.S. Patent No. 5,676,977 discloses intravenously injected tetrasilver tetroxide crystals used for destroying the AIDS virus, ALDS synergistic pathogens, and immunity suppressing moieties (ISM) in humans.
- the crystals were formulated for a single injection at about 40 ppm of human blood.
- This reference also discloses the compositions cause hepatomegaly, also known as enlarged liver, albeit with no reported loss of liver function.
- the aforementioned references report detailed descriptions of the mechanism via which the multivalent silver molecular crystal devices were believed to operate.
- the other unique property of the tetroxide was that it did not stain organic matter such as skin in like manner as Ag(I) compounds do. In addition, it was light stable. Thus, it is desired to find pharmaceutical compositions and methods for preventing, treating, or managing one or more cancers or associated conditions. It is also desired to facilitate the prevention of future outbreaks of one or more disorders, as well as preventing, treating, and managing one or more cancerous or related disorder while avoiding the adverse effects present in many conventional treatments.
- the present invention relates to a method for preventing, treating, or managing one or more cancerous conditions or dysplastic proliferations in an animal.
- the method preferably comprises administering at least one metal oxide compound or a pharmaceutically acceptable derivative thereof, to the animal.
- the metal oxide compound or derivative thereof preferably comprises a first metal cation having a first valence state and a second metal cation having a second, different valence state, such as, for example, an electron active metal oxide compound.
- the at least one metal oxide compound or a pharmaceutically acceptable derivative thereof is preferably administered in an amount and for a period of time which is therapeutically effective to treat such condition(s).
- the at least one metal oxide compound or pharmaceutically acceptable derivative thereof comprises at least one of Bi(IIIN) oxide, Co(LI,III) oxide, Cu(I,ILI) oxide, Fe(II,III) oxide, Mn(LL,LIL) oxide, Pr(III,LV) oxide, or Ag(L,LII) oxide.
- the metal oxide compound or derivative thereof is preferably substantially free of added persulfate.
- the invention is preferably adapted to preventing, treating, or managing systemic cancerous conditions.
- the animal is an mammal, such as, for example, a human.
- the metal oxide compound is preferably administered via intravenous injection or infusion, when the animal is a human.
- the intravenous injection or infusion is preferably subcutaneous, intramuscular, or comprises infusion into the bloodstream of the animal.
- the administration provides an amount of the metal oxide sufficient to provide about 1 to about 75 ppm of the metal oxide compound or derivative thereof in the bloodstream.
- the metal oxide is preferably administered via infusion over a period of time sufficient to inhibit adverse side effects, such as over a time period of from about 30 minutes to about 300 minutes.
- the metal oxide compound or derivative thereof may preferably be administered by a controlled release vehicle.
- the controlled release vehicle is preferably implanted in the body at a location suitable for providing a therapeutically effective amount of metal oxide compound or derivative thereof to the patient, preferably, without affecting proper functioning of the animal's liver.
- the method of the invention is preferably suitable for cancers or dysplastic proliferations including at least one of colon cancer, lung cancer, throat cancer, breast cancer, kidney cancer, pancreatic cancer, bladder cancer, prostate cancer, uterine cancer, brain cancer, liver cancer, skin cancer, testicular cancer, stomach cancer, adrenal gland cancer, cancer of the ovaries, thyroid cancer, bronchial cancer, tracheal cancer, eye cancer, bone cancer, cervical cancer, oral cavity cancer, soft tissue cancer, pituitary gland cancer, myeloma , rectal cancer, esophageal cancer, leukemia, lymphoma, cancerous fibroid tumors, non-cancerous fibroid tumors, or liver cancer.
- the method is preferably suitable for cancers including skin cancer that has metastasized.
- the metal oxide compound or derivative thereof is administered in conjunction with at least one other chemotherapeutic agent.
- the at least one other chemotherapeutic agent is preferably administered concurrently with the metal oxide compound or derivative thereof.
- Another embodiment of the invention relates to a method for preventing, treating, or managing one or more cancerous conditions or dysplastic proliferations associated with a patient's skin, which method preferably comprises administering at least one metal oxide compound or a pharmaceutically acceptable derivative thereof to the skin in an amount and for a period of time which is therapeutically effective to treat such cancerous or associated condition(s).
- the metal oxide compound or derivative thereof preferably comprises a first metal cation having a first valence state and a second metal cation having a second, different valence state.
- the at least one metal oxide compound or pharmaceutically acceptable derivative thereof comprises at least one of Bi(LIIN) oxide, Co(II,III) oxide, Cu(L,III) oxide, Fe(II,III) oxide, Mn(II,III) oxide, Pr(III,IV) oxide, or Ag(I,III) oxide.
- the metal oxide compound or derivative thereof is preferably substantially free of added persulfate.
- the method of the invention is preferably suitable for preventing, treating, or managing cancerous conditions or dysplastic proliferations comprising at least one of dysplastic nevi, neurofibromatosis, basal cell carcinoma, squamous carcinoma, or melanoma.
- the method is preferably suitable for preventing, treating, or managing conditions comprising symptoms of cancer or conditions associated with a predisposition to cancer, such as neurofibromatosis.
- the administering preferably comprises a carrier medium in which the at least one metal oxide compound or pharmaceutically acceptable derivative thereof, is dispersed.
- the therapeutically effective amount of the metal oxide or derivative thereof is from about 50 ppm to 500,000 ppm, such as from about 400 ppm to about 100,000 ppm, based on the weight of the carrier medium.
- the carrier medium may preferably comprise petroleum jelly.
- the administering of the composition is preferably topical or transdermal, such as directly to the skin.
- the at least one metal oxide compound or pharmaceutically acceptable derivative thereof further comprises a thixotropic agent sufficient to increase adherence of the composition to the skin without excessive runoff.
- the at least one metal oxide compound or pharmaceutically acceptable derivative thereof may, preferably, be administered in the form of a powder, such as in the form of metal oxide crystals.
- the administering of the powder is preferably topical or transdermal, such as directly to the skin.
- the metal oxide or derivative thereof is administered at a dosage level of about 10 mg to 500 mg per cm ⁇ of skin surface.
- a preferred embodiment of a composition suitable for application as a powder comprises about 5% metal oxide, such as tetrasilver tetroxide, and about 95% ⁇ bismuth subgallate.
- Yet another embodiment of the invention relates to a method for preventing, treating, or managing one or more cancerous conditions associated with a cervix of a female animal.
- the method preferably comprises admimstering at least one metal oxide compound or a pharmaceutically acceptable derivative thereof to the cervix in an amount and for a period of time which is therapeutically effective to treat such cancerous or associated condition(s).
- Each metal oxide compound or derivative thereof preferably comprises a first metal cation having a first valence state and a second metal cation having a second, different valence state.
- the at least one metal oxide compound or pharmaceutically acceptable derivative thereof comprises at least one of Bi(IILN) oxide, Co(LL,LII) oxide, Cu(I,III) oxide, Fe(II,III) oxide, Mn(LL,LLI) oxide, Pr(III,IV) oxide, or Ag(I,III) oxide.
- the metal oxide compound or derivative thereof is preferably substantially free of added persulfate.
- the metal oxide compound or derivative thereof are preferably applied directly to the cervix.
- the administering preferably comprises a carrier medium, such as petroleum jelly, in which the at least one metal oxide compound or pharmaceutically acceptable derivative thereof, is dispersed, preferably in a therapeutically effective amount from about 50 ppm to 500,000 ppm, based on the weight of the carrier medium.
- the at least one metal oxide compound or pharmaceutically acceptable derivative thereof is preferably applied in an amount sufficient to obtain a desired effect and to substantially inhibit undesirable side effects.
- patient or “subject” as used herein refer to animals, particularly to mammals. In a preferred embodiment, the terms “patient” or “subject” refer to humans.
- the terms "adverse effects,” “adverse side effects,” and “side effects” include, but are not limited to, staining of the skin, headache, dry mouth, constipation, diarrhea, gastrointestinal disorders, dry skin, staining of the skin, hepatomegaly, fever, fatigue, and the like.
- therapeutically effective amount when used herein in connection with the compositions and methods of the invention, means that amount of metal oxide composition, or a derivative thereof, which, alone or in combination with other drugs or treatment modalities, provides a therapeutic benefit in the prevention, treatment, or management, of one or more of forms of cancer or a symptom or related condition thereof.
- the therapeutically effective amount of a component yields the desired therapeutic benefit without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention.
- substantially free means less than about 10 weight percent, preferably less than about 5 weight percent, more preferably less than about 1 weight percent, and most preferably less than about 0.1 weight percent of added persulfate is present according to the invention. Ln another embodiment, the term “substantially free” refers to the same amounts of other added oxidizing agents present in the compositions.
- controlled-release component in the context of the present mvention is defined herein as a compound or compounds, including polymers, polymer matrices, gels, permeable membranes, liposomes, microspheres, or the like, or a combination thereof, that facilitates the controlled-release of the active ingredient (e.g., tetrasilver tetroxide) in the pharmaceutical composition.
- active ingredient e.g., tetrasilver tetroxide
- compositions comprising at least one oxide compound or a pharmaceutically acceptable derivative thereof can be used as advantageous active ingredients in the prevention, treatment, or management of various cancerous conditions.
- the oxide compound preferably comprises a metal oxide, such as an electron active metal oxide.
- the metal oxide compound or pharmaceutically acceptable derivative thereof preferably comprise a first metal cation having a first valence state and a second metal cation having a second, different valence state.
- a species such as a metal cation
- the at least one metal oxide compound or a pharmaceutically acceptable derivative comprises at least one electron active metal oxide compound, such as, for example, at least one of Bi(III,V) oxide, Co(II,III) oxide, Cu(l,III) oxide, Fe(II,III) oxide, Mn(II,III) oxide, Pr(III,IV) oxide, or Ag(I,III) oxide.
- Preferred compounds of the invention comprise at least one metal tetroxide, such as silver tetroxide.
- metal tetroxide and metal tetraoxide are synonymous as used herein.
- the metal oxide compound compositions are substantially free of added persulfate or other added oxidizing agents, since, when applied topically, such agents may cause adverse effects, such as skin irritation and skin over-drying.
- the compositions are substantially free of any oxidizing agents. More particularly, the invention relates to methods for preventing, treating, and managing cancerous conditions and conditions associated with cancer.
- the compositions include a molecular scale device comprising at least one crystal of a metal oxide compound. A plurality of these metal oxide crystals, such as on the order of trillions, may be employed in various pharmaceutical formulations and therapies to effectuate the prevention, treatment, and/or management of various cancers and conditions associated with cancer.
- the compositions of the invention include powders comprising metal oxide crystals of the invention.
- compositions and methods of the invention advantageously provide a desired effect such as preventing, treating, or managing cancer or conditions associated with cancer.
- Management includes controlling one or more cancers, or conditions associated with such cancer(s), that cannot be cured completely, reducing the severity of affliction of such cancers or related conditions, and the like.
- a preferred embodiment of the invention relates to a method of inducing cytotoxicity (cell killing) in cancer cells or reducing the viability of cancer cells.
- the invention relates to the treatment or management of cancer and/or diseases or conditions associated with cancer, while in another embodiment the invention relates to the prevention, of cancer and/or diseases or conditions associated with cancer.
- Preferred metal oxides of the invention comprise a first metal cation having a first valency state and a second metal cation having a second valency state, which differs from the first valency, preferably by at least one charge.
- the first and second metal cations are preferably the same metal.
- the metal oxides of the present invention operate by transferring electrons between cations of differing valency, the electrons contributing to the death of the cancer cells by traversing the cell membrane.
- the crystal lattice of a silver tetroxide (Ag4 ⁇ 4 ) molecular device operates against cancer, tumors, or cells associated with cancer by transferring electrons from its two monovalent silver ions to the two trivalent silver ions in the crystal, contributing to the death of the cancer cells by traversing their cell membrane surface. This in effect "electrocutes" the cancer cells.
- the electrons are forced out of their balanced crystals by such labile groups as NH, ML?, S-S, and SH associated with the cellular surface. Normal cells are not believed to be affected, because they are not believed to proliferate fast enough to expose these labile bonds.
- the metal oxides of the invention are preferably stable as determined by the dissociation constants of the compounds.
- the dissociation constant (K ) of Ag 4 O 4 is 7.9 x 10 ⁇ 13. Therefore the molecule is not beheved to be disturbed unless more stable complexes are formed with such ligands as those associated with the cancer cell membrane surface in a dynamic state.
- the end result of the electron transfer which is a redox reaction, is believed to result in the metal ions of a lower valency being oxidized to a higher valency state and metal ions of a higher valency state being reduced to a lower valency state.
- the pure tetroxide compositions according to the invention could be applied to, for example, the skin without any ill effects or evidence of irritation, despite the fact that the compositions of the invention can be a powerful oxidizing agent.
- the metal oxides of the invention are applied directly in a powder or composition form to afflicted areas, such as the skin, cervix, or cervical pelvic region of an animal afflicted with cancer.
- Preferred routes of administration include topically and application to mucosa. Application can be made, for example, digitally or using a suitable applicator.
- One embodiment of the present invention relates to compositions and methods of using the metal oxide compositions of the invention while minimizing the amount of additional oxidizer, such as persulfate. It has been found in accordance with the present invention that the additional oxide is not required and in some circumstances is undesirable when the oxide is applied to, for example, the skin or cervix, in part due to the undesirable side effect of irritation.
- the compositions are substantially free of added persulfates, while in a preferred embodiment, the compositions are completely free of added persulfates.
- the compositions are substantially free of added oxidizer, while in another preferred embodiment they are completely free of added oxidizer.
- compositions may be applied topically or to mucosa associated with, for example, the skin, cervix, vagina, or colon.
- the metal oxide compound such as tetrasilver tetroxide, may be black in color, such that care must be taken when formulating suitable topical pharmaceutical compositions according to the invention to inhibit or avoid blackening or staining of the skin.
- suitable topical pharmaceutical compositions according to the invention may be black in color, such that care must be taken when formulating suitable topical pharmaceutical compositions according to the invention to inhibit or avoid blackening or staining of the skin.
- the pharmaceutical compositions preferably have an insufficient amount of metal oxide compound to cause visible skin staining.
- the metal oxide compositions according to the invention may be combined with a carrier at an amount from about 5 ppm to 500,000 ppm, more preferably from about 50 ppm to 250,000 ppm of the metal oxide composition, based on the weight of the carrier.
- the compositions are provided in amounts from about 400 ppm to 100,000 ppm, from about 1,000 ppm to 70,000 ppm, from about 10,000 ppm to 50,000 ppm, or from about 20,000 ppm to 40,000 ppm.
- the compositions are formulated with about 25,000 ppm to 35,000 ppm of metal oxide.
- the administration of 0.005 g of metal oxide to an adult human being provides about 1 ppm of the metal oxide in the bloodstream of the human.
- the concentration of the metal oxide crystals dispersed in the carrier ranges from about 0.1 to 10% by weight, more preferably from about 0.25 to 5% by weight and most preferably from about 2 to 4% by weight.
- the compositions, when applied topically, can be applied to the skin about 1 to 3 times per day until the condition is suitably cured or satisfactorily controlled.
- the composition may generally be topically applied at a dosage level of from about 1 mg to 1000 mg per cm 2 of skin surface, preferably about 10 mg to 500 mg per cm 2 of skin surface.
- a preferred carrier for topical formulations and administration includes petroleum jelly, such as white petroleum jelly.
- white petroleum jelly such as white petroleum jelly.
- a suitable white petroleum j elly is available from Penreco of Houston, TX..
- a preferred mode of application of the oxide of the invention is as an ointment.
- suitable formulations include, but are not limited to, salves and the like. If desired, these may be sterilized or mixed with auxiliary agents, e.g., thixotropes, stabilizers, wetting agents, and the like.
- Preferred vehicles include ointment bases, e.g., polyethylene glycol-1000 (PEG-1000); conventional ophthalmic vehicles; creams; and gels, as well as petroleum jelly and the like.
- the cancerous conditions and diseases that may be prevented, treated, or managed with the compositions of the mvention vary and include, but are not limited to, cancers including any of the various malignant neoplasms, tumors, or cells, such as, for example, those marked by a proliferation of anaplastic cells.
- cancer includes any cancers that involve specific organs or regions of the body such as the colon, lung, throat, breast, kidney, pancreas, bladder, prostate, uterus, brain, liver, skin, testicles, stomach, adrenal gland, ovaries, thyroid, rectum, bronchus, trachea, eye, bone, cervix, oral cavity, soft tissue, pituitary gland, myeloma, rectum, esophagus or liver.
- the invention is also suited for the prevention, treatment, or management of cancerous fibroid tumors and non-cancerous fibroid tumors.
- leukemia which is a malignant overproduction of white blood cells, lymphoma, and metastasized melanoma which has proliferated from skin via blood and/or the lymphatic system.
- Conditions or diseases associated with a predisposition to cancer such as, for example, neurofibromatosis are also included.
- the present invention preferably allows treatment or management of conditions or diseases associated with a predisposition to cancer even if those conditions or diseases have not fully progressed to a cancerous or malignant stage.
- the present invention is also adapted to treating or managing atypical proliferations of cells, such as those characterized by nuclear enlargement and failure of maturation and differentiation. Such proliferations may be short of malignancy.
- Atypical proliferations suitable for treatment, management, or prevention by the present invention include dysplasia or dysplastic proliferations, such as dysplastic nevi or neurofibromatosis, which are recognized by alterations in the appearance of cells (cytology).
- Dysplastic cells may have some of the features of malignant cells but the changes are less pronounced. As the dysplasia progresses, the nuclei of cells become more hyperchromatic and the nuclear membranes become more irregular; the size of the nucleus increases and the cytoplasm does not increase proportionately, so the that the nuclea ⁇ cytoplasmic ratio increases.
- Different therapeutically effective amounts and deliver systems may be applicable for each disorder, as will be readily known or determined by those of ordinary skill in the art.
- Tumors or neoplasms include new growths of tissue in which the multiplication of cells is uncontrolled and progressive. Some such growths are benign, but others are termed “malignant,” leading to death of the organism. Malignant neoplasms or “cancers” are distinguished from benign growths in that, in addition to exhibiting aggressive cellular proliferation, they invade surrounding tissues and metastasize. Moreover, malignant neoplasms are characterized in that they show a greater loss of differentiation (greater "dedifferentiation"), and a greater loss of their organization relative to one another and their surrounding tissues. This property is also called “anaplasia.”
- Neoplasms preventable, treatable, or manageable by the present invention include all solid tumors, i.e., carcinomas and sarcomas.
- Carcinomas include those malignant neoplasms derived from epithelial cells which tend to infiltrate (invade) the surrounding tissues and give rise to metastases.
- Adenocarcmomas are carcinomas derived from glandular tissue or in which the tumor cells form recognizable glandular structures.
- Sarcomas broadly include tumors whose cells are embedded in a fibrillar or homogeneous substance like embryonic connective tissue.
- the invention can also be practiced by administering the metal oxide compositions in conjunction with one or more other anti-cancer compatible chemotherapeutic agents, such as any conventional chemotherapeutic agent.
- the combination of the metal oxide with such other agents can potentiate the chemotherapeutic protocol.
- Numerous chemotherapeutic protocols will present themselves in the mind of the ordinary-skilled practitioner as being capable of use according to the methods of the invention.
- Any compatible chemotherapeutic agent can be used, including antimetabolites, hormones and antagonists, radioisotopes, as well as natural products.
- the metal oxide can be administered with taxol and its natural and synthetic derivatives, and the like, and combinations thereof.
- the metal oxide in the case of mixed tumors, such as adenocarcmomas of the breast and prostate, in which the tumors can include gonadotropin-dependent and gonadotropin-independent cells, the metal oxide can be administered in conjunction with leuprolide or goserelin (synthetic peptide analogs of LH-RH), or both.
- Other antineoplastic protocols include the use of a metal oxide with another treatment modality, e.g., surgery, radiation, other chemotherapeutic agent, etc., referred to herein as "adjunct antineoplastic modalities.”
- the method of the invention can be employed with such conventional regimens with the benefit of reducing side effects and enhancing efficacy.
- These other anti-cancer chemotherapeutic agents and modalities may be administered either concurrently or sequentially with the metal oxide compositions of the invention.
- a preferred metal oxide for use according to the mvention, tetrasilver tetroxide, has been commercially sold under the poorly named " Ag(LL) OXIDE” fradename. Lt may also be obtained from Aldrich Chemical Co., Milwaukee, WI.
- the chemical synthesis of silver oxide compounds according to the invention can be performed according to the method described on page 148 in M. Antelman, "Anti-Pathogenic Multivalent Silver Molecular Semiconductors," Precious Metals, vol. 16:141-149 (1992) by reacting silver nitrate with potassium peroxydisulfate according to the following equation in alkali solutions:
- a prophylactic or therapeutic dose of metal oxide composition(s), or a derivative thereof, in the acute or chronic management of diseases and disorders described herein will vary with the severity of the condition to be prevented, treated, or managed and the route of administration.
- oral, mucosal (including vaginal and rectal), parenteral (including subcutaneous, intramuscular, bolus injection, and intravenous, such as by infusion), sublingual, transdermal, nasal, buccal, and like may be employed.
- Dosage forms include tablets, troches, lozenges, dispersions, suspensions, suppositories, solutions, capsules, soft elastic gelatin capsules, patches, and the like.
- the dose, and perhaps the dose frequency, will also vary according to the age, body weight, and response of the individual patient. Suitable dosing regimens can be readily selected by those of ordinary skill in the art with due consideration of such factors.
- the total daily dosage for the conditions described herein can be from about 1 mg to 500 mg of the metal oxide or derivative thereof, while in another embodiment, the daily dosage can be from about 2 mg to 200 mg of the metal oxide composition.
- a unit dosage can include, for example, 30 mg, 60 mg, 90 mg, 120 mg, or 200 mg of metal oxide composition.
- the active ingredient is administered in single or divided doses from one to four times a day.
- compositions are administered by an oral route of administration.
- oral dosage forms may be conveniently presented in unit dosage forms and prepared by any methods available to those of ordinary skill in the art of pharmacy.
- the therapy may be initiated at a lower dose, e.g., from about 1 mg, and increased up to the recommended daily dose or higher depending on the patient's global response. It is further recommended that children, patients over 65 years, and those with impaired renal or hepatic function, initially receive low doses when administered systemically, and that they be titrated based on individual response(s) and blood level(s). It may be necessary to use dosages outside these ranges in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with individual patient response.
- Any suitable route of administration may be employed for providing the patient with an effective dosage of metal oxide, or a pharmaceutically acceptable derivative thereof.
- the most suitable route in any given case will depend on the nature and severity of the condition being prevented, treated, or managed.
- One preferred route is parenterally, preferably intravenously. Ln this embodiment, a preferred intravenous route of administration is by infusion.
- compositions of the present invention include, but are not limited to, suspensions, solutions and elixirs; aerosols; or carriers, including, but not limited to, starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like.
- Another suitable route of administration of the silver tetroxide compositions of the invention is topically, e.g., either directly as a powder or in non-sprayable or sprayable form.
- Topical administration is a preferred route of administration for treating topical cancerous conditions, such as skin cancer that has not metastasized or cervical cancer.
- the metal oxide may be applied topically to the affected skin areas directly in powder form or in compounded formulations.
- Non-sprayable forms can be semi-solid or solid forms including a carrier indigenous to topical application and preferably having a dynamic viscosity greater than that of water.
- Suitable formulations include, but are not limited to, suspensions, emulsions, creams, ointments, powders, liniments, salves and the like. If desired, these may be sterilized or mixed with any available auxiliary agents, carriers, or excipients, e.g., thixotropes, stabilizers, wetting agents, and the like.
- One or more thixotropic agents can be included in types and amounts sufficient to increase adhesion of topically applied compositions of the invention to a surface or mucosa associated with a treatment zone such as, for example, the skin, vagina, or cervix, so as to inhibit or prevent runoff or other loss of the composition from the treatment zone, particularly when the compositions are formulated for topical administration.
- a treatment zone such as, for example, the skin, vagina, or cervix
- the compositions preferably prevent, treat, or manage such conditions or diseases without visibly staining the skin, i.e., no staining to the naked eye.
- Preferred vehicles for non-sprayable topical preparations include ointment bases, e.g., polyethylene glycol-1000 (PEG-1000); conventional ophthalmic vehicles; creams; and gels, as well as petroleum jelly and the like.
- the carrier includes a petroleum jelly.
- the carrier is formulated as a cream, gel, or lotion.
- a preferred composition comprises about 3% metal oxide, such as tetrasilver tetroxide, about 47% white petrolatum, about 36% heavy mineral oil, and about 14% TTVAWAX P Tivian Laboratories Inc., Buffalo, RI.
- These topical preparations may also contain emollients, perfumes and/or pigments to enhance their acceptability for various uses.
- a metal oxide, or a derivative thereof is formulated for parenteral administration by injection (subcutaneous, bolus injection, intramuscular, or intravenous, such as by infusion), and may be dispensed in a unit dosage form, such as a multidose container or an ampule.
- Parenteral administration is a preferred administration route when the cancer is systemic, i.e., has a locus inside the body.
- the formulation adapted for parenteral administration includes an insufficient amount of persulfate to induce irritation or adverse side effects.
- the formulation is substantially free of added persulfate, while in another more preferred embodiment, the formulation is completely free of added persulfate.
- the dosage When administered intravenously, such as by infusion, the dosage preferably provides a concentration of the metal oxide in the blood stream of about 1 ppm to about 75 ppm, more preferably from about 5 ppm to about 50 ppm, such as from about 10 ppm to about 40 ppm or about 50 to 200 mg.
- a one-time dosage is infused or injected directly into the bloodstream.
- the intravenous dosage is preferably delivered over a period of time sufficient to substantially inhibit or even avoid the occurrence of side effects.
- the dosage can be delivered by intravenously or by infusion over a time from about 10 minutes to about 300 minutes, preferably from about 20 minutes to about 240 minutes.
- compositions of the metal oxide, or a pharmaceutically acceptable derivative thereof, for parenteral administration may be in the form of suspensions, solutions, emulsions, or the like, in aqueous or oily vehicles, and in addition to the active ingredient may contain one or more formulary agents, such as dispersing agents, suspending agents, stabilizing agents, preservatives, and the like.
- compositions of the present invention may be orally administered in discrete pharmaceutical unit dosage forms, such as capsules, cachets, soft elastic gelatin capsules, tablets, or aerosols sprays, each containing a predetermined amount of the active ingredient, as a powder or granules, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
- Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing into association the active ingredient with the pharmaceutically acceptable carrier which constitutes one or more necessary ingredients.
- compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
- suitable types of oral administration include oral solid preparations, such as capsules or tablets, or oral liquid preparations.
- tablets may be coated by standard aqueous or non-aqueous techniques.
- a tablet may be prepared by compression or molding, optionally, with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, granulating agent, surface active agent, dispersing agent, or the like. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- each tablet, capsule, cachet, or gel cap contains from about 0.5 mg to about 500 mg of the active ingredient, while in another embodiment, each tablet contains from about 1 mg to about 250 mg of the active ingredient.
- the amount of active ingredient found in the composition may vary depending on the amount of active ingredient to be administered to the patient.
- transdermal delivery for example, via an abdominal skin patch.
- the metal oxide, or a suitable derivative thereof, may be formulated as a pharmaceutical composition in a soft elastic gelatin capsule unit dosage form by using conventional methods well known in the art, such as in Ebert, Pharm. Tech, l(5):44-50 (1977).
- Soft elastic gelatin capsules have a soft, globular gelatin shell somewhat thicker than that of hard gelatin capsules, wherein a gelatin is plasticized by the addition of plasticizing agent, e.g., glycerin, sorbitol, or a similar polyol.
- plasticizing agent e.g., glycerin, sorbitol, or a similar polyol.
- the hardness of the capsule shell may be changed by varying the type of gelatin used and the amounts of plasticizer and water.
- the soft gelatin shells may contain a preservative, such as methyl- and propylparabens and sorbic acid, to prevent the growth of fungi.
- the active ingredient may be dissolved or suspended in a liquid vehicle or carrier, such as vegetable or mineral oils, triglycerides, surfactants such as polysorbates, or a combination thereof.
- the metal oxide can be delivered via a controlled release delivery vehicle.
- the controlled release vehicle includes a polymeric material, delivered or surgically implanted at or near the lesion site.
- controlled release means and delivery devices such as those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548;
- compositions can be used to provide slow or controlled-release of the active ingredient therein using, for example, hydropropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or the like, or a combination thereof.
- Suitable controlled-release formulations available to those of ordinary skill in the art, including those described herein, may be readily selected for use with the the metal oxide compositions of the invention.
- single unit dosage forms suitable for topical, parenteral, or oral administration such as infusions, intravenous drips, gels, lotions, cremes, tablets, capsules, gelcaps, caplets, and the like, that are adapted for controlled-release are encompassed by the present invention.
- All controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts.
- the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time.
- Advantages of controlled-release formulations may include: 1) extended activity of the drug; 2) reduced dosage frequency; and 3) increased patient compliance.
- controlled-release formulations are designed to initially release an amount of drug that promptly produces the desired therapeutic effect, and gradual and continual release of other amounts of drug to maintain this level of therapeutic effect over an extended period of time. Ln order to maintain this constant level of drug in the body, the drug should be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.
- the controlled-release of the active ingredient may be stimulated by various inducers, for example pH, temperature, enzymes, water, or other physiological conditions or compounds.
- the pharmaceutical compositions for use in the present invention include the metal oxide, or a derivative thereof, as the active ingredient, and may also contain a pharmaceutically acceptable carrier, and optionally, other therapeutic ingredients. Suitable derivatives include any available "pharmaceutically acceptable salts," which refer to a salt prepared from pharmaceutically acceptable non-toxic acids including inorganic acids, organic acids, solvates, hydrates, or clathrates thereof. Preferably, in the case of silver (1,111), the salts do not comprise halides.
- organic acids examples include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, and phosphoric.
- Appropriate organic acids may be selected, for example, from aliphatic, aromatic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, citric, fumaric, gluconic, isethionic, lactic, malic, mucic, tartaric, para-toluenesulfonic, glycolic, glucuronic, maleic, furoic, glutamic, salicylic, mandelic, methanesulfonic, ethanesulfonic, benzenesulfonic (besylate), sulfanilic, alginic, galacturonic, and the like.
- Particularly preferred acids phosphoric, methanesulfonic, and glycolic.
- EXAMPLE 1 Treatment of Breast Cancer According to the Invention A subject group was formed of thirty female residents of Central
- Each subject was evaluated daily by an oncologist(s) and each received a single dosage of tetrasilver tetroxide by TV, i.e., intravenously, sufficient to provide a concentration in the bloodstream of 10 ppm.
- TV i.e., intravenously
- One-half of the patients received the dosage in 10 minutes by IV injection.
- the other half of the subjects received the dosage by IN inj ection over a 4-hour period.
- the subjects were arranged in three histology groups. Within each histologic group, 50%> of the subjects received the dosage via the 10 minute LV and the other 50 %> of the subjects received the dosage over the 4 hour period of time. Prior to initiating freatment, the tetrasilver tetroxide was subj ected a quality assurance protocol to reduce side effects.
- Group I Group I included 10 patients who had been diagnosed as having infiltrative canalicular breast carcinoma.
- a 1 cm diameter biopsy fragment was sent to a pathologist laboratory.
- the pathologist reported an increase of the dense fibrous tissue, anaphasic cells in the gland ducts, forming lines, tubes, ducts, glands and cell anastomosis.
- the histologic report confirmed the diagnosis of the 10 patients in this group: infiltrative canalicular breast carcinoma.
- Group II Group II included 10 subjects were diagnosed as having ductile carcinoma special type, medular breast cancer.
- Group III Group III included ten patients diagnosed as having infiltrative lobular breast cancer. For each of the three groups, the dosage was 10 ppm for every subject.
- the oncologist ordered a new biopsy of this group.
- the pathologist reported 100%) of the biopsies as mtralobular ducts normal in number and size. No change in shapes. Cylindric cells in the mammary ducts were normal in shape and in size. Basal membranes were intact. Diagnosis: normal mammary tissue.
- liver function tests did not reveal abnormalities. Sodium, potassium, and magnesium blood levels decreased. Albumin, bilirubin calcium, cholesterol, creatinine, LDH, AST, SGOT, and triglyceride remained normal.
- the oncologist ordered a new biopsy of Group II.
- the biopsy was acquired after 24 days of treatment.
- the oncologist reported that there were no more hemorrhaging and necrosis zones in the breast tissue.
- the pathologist reported 90%> of the biopsy as intralobular ducts normal in number and size. No change in shape and normal mitosis was observed.
- Cilindric cells in the mammary ducts were normal in shapes and in sizes and basal membranes were intact. Diagnosis: normal mammary tissue.
- Group III At 5 days after treatment, the nipple retraction, bleeding from the nipple, the distorted areola, and the attachment of the mass to surrounding tissues were almost gone. The average nodule size decreased from 4 cm to 2.6 cm. At day number 20 after freatment, the refracted nipples, the bleeding from the nipple, the distorted areola and the attachment of the mass to surrounding tissues was in 90% remission. The average size of the nodules had decreased further from 2.6 cm to 1 cm. None of the patients of this group that had received direct injection exhibited an increase in the body temperature or even slight liver enlargement. The red blood cells count was normal, and the white blood cells remained normal. The electrocardiogram did not reveal abnormalities. Sodium , potassium, and magnesium blood levels deceased. Albumin, bilirubin calcium, cholesterol, creatinine, LDH, AST, SGOT and triglyceride remained normal.
- the oncologist ordered a new biopsy of this group.
- the pathologist reported 80% of the biopsies as intralobular ducts normal in number and size. No change in shape. Cilindric cells in the mammary ducts normal in shape and in size and the basal membranes were intact. Diagnosis: normal mammary tissue.
- Tetrasilver tetroxide is preferably delivered in an IV solution to inhibit undesirable side effects.
- Tetrasilver tetroxide administered by IV appears to stop the growth of the breast cancer.
- Tetrasilver tetroxide appears to stimulate the normal breast cells and allows them to replace the anaphasic cells in the breast carcinoma.
- Tetrasilver tetroxide appears to cure infiltrative breast carcinoma in a 24 day period.
- Tetrasilver tetroxide appears to cure ductile carcinoma special type, medular breast carcinoma in a 30 day period.
- Tetrasilver tetroxide appears to cure infiltrative lobular breast cancer in a 30 days period. 7. Although certain patients developed mild cases of hepatomegaly, the liver functioning was not impaired as evidenced by the normal levels of liver function enzymes in the blood stream.
- Paget's disease of the nipple is a rare type of carcinoma that appears as a unilateral dermatitis of the nipple and represents extension to the epidermis of an underlying mammary duct carcinoma. The redness, oozing, and crusting closely resemble dermatitis, but the physician should suspect carcinoma because the lesion is unilateral.
- Group 1 Group I included 13 patients with Paget's disease of the nipple, with an average depth of invasion of 0.76 to 1.5mm. All of the laboratory results indicated the same diagnosis and were taken weekly for 4 weeks. Each patient in this group exhibited metastasis. The lesions were all ulcered and sized on average from 2.3 cm to 3.4 cm. The treatment protocol began with 200 mg of ointment containing 3% tetrasilver tetroxide 3 times per day as applied by a physician. All of the patients were evaluated daily for 4 weeks. None of the patients received anterior treatment.
- Group II Group II included 12 patients suffering from Paget's disease of the nipple, with an average depth of invasion of 2.26 cm to 3.0 cm. All the laboratory results for 4 weeks confirmed the diagnosis. The lesions were all ulcered and sized from an average of 4.3 cm to 5.2cm. The treatment protocol began with 200 mg of ointment containing 3% tetrasilver tetroxide 3 times per day as applied by a physician. All of the patients were evaluated daily for 4 weeks. None of the patients had anterior treatment. Results of Paget's Disease Treatment
- Group I Over a period of 15 days, the lesions from Paget's disease began to regress and dry out in all the patients. Pain was gone and the patients began to regain an appetite. The color of the lesions changed from a red more to white. At day 27 of the study, all of the lesions were healed and the lesions were not visible at all. No recurrences of lesions were observed. The last biopsy showed minimum amount of atypical cells, and the mammary ducts were normal.
- a study group was formed of twelve patients aged between 45 and 65 years. Each patient had been diagnosed with ulcerative Rhabdomyosarcoma. A pathologist confirmed the diagnosis of each patient based upon a biopsy. All the patients were Caucasian and had similar exposures to sunlight during their lifetimes. All patients had infections demonstrating the presence of pathogens received during chemotherapy and surgical resection treatment. None of the patients exhibited signs of metastasis. As discussed below, the patients were divided into two groups.
- Group I Group I was formed of seven patients with confirmed biopsy diagnosis of ulcerative Rhabdomyosarcoma with extreme infection. Each patient exhibited ulcerative injuries at the inferior member with an extension of 9 cm to 12 cm in diameter. The ulcers exhibited serosanguinous secretions in abundance. The evaluation period began from 4 to 7 months prior to initiating treatment with 3%> tetrasilver tetroxide. Each patient started treatment with 200 mg of ointment 3%, three times a day for 30 days.
- Group II Group II was formed of five patients with confirmed biopsy diagnosis of ulcerative Rhabdomyosarcoma with extreme infection. Each case presented extensive ulcerative injuries with indurated edges larger than 12 cm in diameter. The period of evaluation was more than 7 months and all the patients received chemotherapy and surgical resection. Each patient was treated with ointment of 3%> of tetrasilver tetroxide of the invention three times a day for thirty days.
- Group I All patients experienced a commencement of healing of the ulcers by day 27 from the start of the treatment. The regions of irritation receded and the color of the lesions became darker and more similar to normal skin color. By day 30, the ulcers were dry and began the scarring process. A biopsy control preformed at the 30 th day revealed normal muscular tissue with no signs of metaplasia. At the 40 th day of treatment, a biopsy control was preformed and indicated that the injured metaplastic cells had been replaced by cells of normal appearance. By the 45 th day, the ulcers were no longer visible. The post-treatment evaluations showed no signs of recidivism.
- EXAMPLE 4 Topical Treatment with Tefrasilver Tetroxide on Neurofibromatosis This study was performed to determine the effect of topical freatment with tefrasilver tetroxide on neurofibromatosis. A study group was formed of twelve patients aged 5 months to 3 years who had been diagnosed as having neurofibromatosis. These diagnoses were reconfirmed in conjunction with this study. Diagnoses were made by clinical study and by biopsy of the lesions. None of the patients had received prior treatment. None of the patients exhibited skeletal anomalies or lesions of the optic nerve or acoustic nerve. The patients were arranged in 2 groups as discussed below.
- Group I Group I included eight patients having von Recklinghausen's disease and neurofibromatosis type plexiform neuromas. All of them were symptomatic. The brown spots of the skin were located in the trunk. Each patient applied 200 mg of ointment with 3% tetrasilver tetroxide, 3 times per day for 30 days. Daily evaluations were made to observe progress and to determine the presence of side effects.
- Group II Group II included four patients who had been diagnosed as having von Recklinohausen's disease and neurofibromatosis type neuro fibroma. Each diagnosis was confirmed by biopsy. All of the patients were symptomatic. The lesions were located in the trunk, pelvis, and elbows. All of the patients of this group applied 200 mg of ointment with 3%> of tetrasilver tetroxide 2 times per day for 30 days. Daily evaluations were made to observe progress and determine the presence of side effects.
- Group I By day 20, five of the eight patients were cured of the spot- type skin lesions. No more symptoms were found. The biopsy result showed normal cells and no reoccurrences were observed. The biopsy results of the other 3 patients showed some atypical cells and the spots, although reduced in color, were still visible. Group II: At the end of the study, these patients were still symptomatic and the biopsies confirmed the presence of atypical Schwann tumor cells.
- Tetrasilver tetroxide ointment did not generally seem to produce as thorough a curative result for neurofibroma.
- EXAMPLE 5 Topical Treatment with Tefrasilver Tetroxide on Cervical Carcinoma
- the cervical cancer afflictions are divided into two main categories. The first is based on cervical smear (PAP smear) test results following the Bethesda System for reporting cervical cytologic diagnoses bearing designations CIN- the acronym for cervical intraepithelial neoplasia. The second is based on designated NIC stages of which:
- 0 carcinoma in situ, intraepithelial carcinoma
- CIN 3 Five patients were confirmed as CIN 3, i.e., having high grade squamous intraepithelial lesions, severe dysplasia and carcinoma in situ one month prior to clinical studies.
- the ointment was administered to the patients in conformity with the protocol of Example 1 for 10 days. All patients were cured as confirmed by both cytologist and cytopathologist.
- a study group was formed of thirty-one patients between the ages of 48 and 78 years who had been diagnosed with malignant melanomas. The diagnoses were confirmed by biopsy before the study was conducted. The study group included four subgroups as discussed below.
- Group I Group I included fourteen female patients between the ages of 52 to 70 years. Biopsies confirmed superficial spreading melanomas with a depth of invasion ranging from minor to 0.76 mm. The melanomas were located in the interior extremities ofthe females. Each ofthe patients began treatment with 200 mg of the 3% tetrasilver tetroxide composition in lotion form applied twice a day. The fourteen patients indicated that they had not previously been treated for the melanoma.
- Group II Group II included eight patients ranging between the ages of 65 to 78 years. A biopsy confirmed the presence of lentigo maligna melanoma. Seven ofthe eight patients had a depth invasion of 0.76 mm and one of them exhibited a 1.5mm depth of invasion. Each patient was Caucasian and indicated that they had not previously received treatment. Additional laboratory tests demonstrated no pain or secondary effects in the patients. Each ofthe patients began treatment with 200 mg ofthe lotion at 3%> tetrasilver tetroxide applied three times a day. Group III: Group III included five patients ranging from ages 60 to 70 years old who had been diagnosed with nodular melanoma. The patients had not previously received treatment.
- Group III Three ofthe patients having a depth invasion ranging from minor to 0.76 mm were placed in a subgroup IIIA. Two patients exhibited a depth of invasion ranging 0.51mm to 2.25 mm and were designated group 1LLB. Group IILB included patients ranging in age from 64 to 68 years old. Two of these patients exhibited discomfort associated with the lungs. Group III initiated treatment with 200 mg ofthe lotion at 3% tetrasilver tetroxide applied three times per day for 30 days.
- Group IV Group TV included four patients between the ages of 45 to 54 years old who had been diagnosed with acrolentiginous melanoma. Two ofthe patients had received prior treatment with no success. The depth invasion ranged between 1.51 to 2.25 mm. These two patients were designated Group IVA. The remaining patients, Group IVB, exhibited a depth of invasion ranging from minor to 0.76mm. No discomfort was reported by Group IV patients.
- Group LV began freatment with 200 mg ofthe lotion at 3%> tetrasilver tefroxide applied three times per day for thirty days.
- the eight patients of Group II exhibited improvement by the eighth day of treatment.
- the melanomas ofthe dermis had changed from black and or dark brown to a lighter color.
- the injuries had disappeared.
- a new biopsy was conducted.
- the biopsy indicated that the ratio of malignant melanomas to normal melanocytes, i.e., benign melanomas, had decreased in relation to the pre-study biopsy.
- a biopsy conducted at the twentieth day of treatment indicated normal melanocytes.
- the patients have been monitored without any changes from the above described results.
- the patients of Group IIIA observed that their injuries had begun to heal between the 9th and 10th day ofthe treatment. By the fourteenth day of freatment, the grey colored spots were no longer visible.
- the patients of group INA exhibited no change by the thirtieth day of the treatment. A biopsy obtained at the this time indicated the presence of malignant melanomas.
- the patients of group LVB exhibited changes to the border and color ofthe injuries by the second day of treatment. By the sixth day of freatment, the injuries were not visible and a biopsy acquired at the fifteenth day indicated normal melanocytes.
- compositions healed superficial spreading melanomas within 8 to 14 days of treatment when the depth of invasion was less than 0.76 mm.
- the biopsies indicated that the cancer was eliminated.
- the compositions healed the lentigo-maligna having an invasion depth between 0.76mm to 1.5mm. No discomfort or side effects reported.
- the compositions also eliminated nodular melanoma with a depth invasion of 0.76mm or less within a sixteen day treatment period.
- the compositions did not eliminate the nodular melanoma having a metastasis condition with a depth of invasion of 1.51 mm to 2.25 mm within thirty days in this study.
- compositions ofthe invention were highly effective at treating the acrolentiginous melanoma condition with a depth invasion ranging from minor to 0.76mm (without metastasis).
- the compositions eliminated the cancer in 100%) of these cases.
- the present compositions were an effective treatment for the melanomas where chemotherapy and surgical resources were ineffective.
- the compositions did not, however, have a noticeable effect upon acrolentiginous melanoma with a depth of invasion ranging from 1.5mm to 2.25mm within a period of 30 days of treatment.
- EXAMPLE 7 Preparation of a 3%> Tefrasilver Tefroxide Ointment A paraffinic hydrocarbon ointment was prepared by heating with agitation a mixture comprising about 33 wt %> heavy mineral oil and about 67 wt %> of petroleum jelly to a temperature of 70 °C and then dispersing in this mixture the finely divided tefrasilver tefroxide powder sufficient to provide a 3%> by weight concentration ofthe oxide in the carrier. The mixture was then cooled to room temperature with continuous stirring until the mixture was no longer liquefied. Lt should be understood that the methods of this example can be used in preparing the ointments and lotions of Examples 1-6, as well as other compositions according to the invention, as will be readily understood by those of ordinary skill in the art.
- a male age 47 was diagnosed as having melanoma at least for three years. He exhibited at least 15 blotchy brown lesions scattered on both forearms. The size ofthe affected areas varied from 0.3 mm to 1.2 mm. The ointment of Example 7 was applied to the affected skin areas ofthe arms at least once a day. After one week, the brown blotches had been modified or replaced by pink ones. After 2 weeks, the pink areas were gone. After 3 and 4 weeks, there was no evidence of any melanoma.
- EXAMPLE 9 Treatment of Basal Cell Carcinoma Two patients, one a male age 83 and the other a female age 63, were treated in the same manner as in Example 8 for basal cell carcinoma.
- the female had one large brown cancer growth varying from 0.6-1.4 mm by 0.9-3.6 mm on top ofthe scalp.
- the male had several white head pimples 0.3-0.7 mm. One was on the right ear. Five were on the scalp and another was on the left leg. After one week the female observed that her tumor had diminished to just a minor pink skin irritation. After two weeks, the pink irritation had vanished. After four weeks had elapsed, the skin was clear and normal in appearance.
- the sores were on both arms, with five on the right and seven on the left. Their appearance was oval shaped ranging from 2.5-5.5 mm in length.
- This patient was treated in the same manner as in Example 8 by applying the ointment of Example 7 to the affected skin areas. After one week of treatment, all open sores had closed and were in the process of healing. During the second week, sores continued to heal at a rapid pace. Scabs were completely gone by the end ofthe second week. At the end ofthe third week, only slight pink areas remained in the place ofthe previous sores. By the end ofthe fourth week, there were no traces ofthe previous affliction.
- Group I Group I included ten patients exhibiting injuries of less then lcm in size with nodules that were bright and ulcerated. At the time of diagnosis, no form of treatment had been implemented. The patients had been evaluated for one month prior to treatment with tetrasilver tetroxide composition ofthe invention formulated as an ointment of 3%> tefrasilver tetroxide. Each ofthe affected areas was located in a region ofthe body exposed to sunlight. Each patient began treatment with 200 mg tefrasilver tetroxide ointment 3% ⁇ , three times a day for thirty days. Group II: Group II was formed by 10 patients having injuries larger than 1 cm.
- the injuries were clinically present as nodules that were ulcerated and with indurated edges. In each case, the period of evaluation exceeded one month.
- Each patient began treatment with 200 mg tefrasilver tetroxide ointment 3%>, three times a day for 30 days. Results
- Group I Each patient within this group displayed a healing process of the ulcerated nodules by the seventh day of treatment. It was no longer possible to visualize the irritations and the bright color became darker and more similar to the normal skin. By the twelfth day of treatment, the ulcers were not visible at all and the. scarring process had begun. Controlled biopsies taken at the fifteenth day of treatment indicated that the metaplastic cells from the injuries had been replaced by normal appearing cells. The nodules were smaller than 0.5 cm. By the twenty-fourth day of treatment, the nodules were not visible and only showed a light zone of papular tissue. The biopsy control performed at 30 days revealed normal basal cellular tissue with no signs of metaplastic cells. No recidivism was observed at the thirty day examination.
- Group II Each patient in this group exhibited changes in the nodules up to the fifteenth day of treatment when the beginning ofthe drying process began and the nodules stopped exhibiting signs of peripheral irritation areas.
- Biopsies performed on the 16th day of treatment indicated a reduction in metaplastic cell with newly formed cells. The ration of metaplastic cells to the normal cells began to invert by the tliirtieth day of treatment, and the ulcerated nodules had disappeared and were only indicated by a few light zones.
- Biopsies performed on the thirtieth day revealed that 80%) ofthe affected tissue was occupied by normal basal cells, but also indicated the presence of metaplastic cells. The post-treatment evaluation at 30 days did not clinically indicate any ofthe previous skin injuries.
- Group I had six patients with dermal injuries of 5 to 10 mm.
- Group II had four patients with dermal injuries of more than 12 mm.
- Group I Within 36 hours ofthe onset of treatment, the color and size ofthe injuries began to change, i.e., turn into smaller spots. By the sixth day, the dysplastic nevi were no longer visible. By the eighth day, a biopsy was conducted revealing new normal melanocytes. The patients were evaluated for the duration of the period, with no further changes reported.
- Group II By the fourth day of treatment, changes had started to occur. The color from the spots had started to disappear, and they were also turning smaller. By the fifteenth day, a new biopsy was taken showing normal melanocytes, with the injuries no longer visible. Patients did not experience any further changes in their condition over the 30 days.
- EXAMPLE 13 Cytotoxicity Tumor Cell Proliferation Studies and Evaluations An independent laboratory performed cytotoxicity tumor cell proliferation studies and evaluations. A culture of leukemia K562 was tested in vitro against media concentrations of tetrasilver tetroxide at: 0.5, 1,5, 10, 50, 100, 500 and
- NPS non phosphate non saline
- the cancer cultures were obtained from a cell line provided by the American Type Culture Collection (ATCC) and were incubated at 37°C with 5%> CO 2 in air atmosphere.
- the culture was a human chronic myelogenous leukemia, of cell line source ATCCCCL-243.
- the above methodology was applied to a human malignant melanoma cell line of source ATCCHTB-70 having the cell name SK-MEL-5.
- the culture media comprised 90%> Minimum Essential Medium and fetal bovine serum, 10%. The results were as follows:
- the a IC 50 is the test compound concentration where the increase from time 0 in the number or mass of treated cells was only 50% as much as the corresponding increase in the vehicle-control at the end of experiment.
- the bTGI Total Growth Inhibition is the test compound concentration where the number or mass of treated cells at the end of experiment was equal to that at time.
- the CLC is the test compound concentration where the number or mass of freated cells at the end of experiment was half that at time. Table 1.1 shows other results from this study.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU13396/01A AU784597B2 (en) | 2000-01-06 | 2000-10-20 | Methods of using electron active compounds for managing cancer |
JP2001549669A JP2003519187A (en) | 2000-01-06 | 2000-10-20 | Methods of using electronically active compounds for cancer management |
EP00975330A EP1246629A4 (en) | 2000-01-06 | 2000-10-20 | Methods of using electron active compounds for managing cancer |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17479300P | 2000-01-06 | 2000-01-06 | |
US60/174,793 | 2000-01-06 | ||
US18405300P | 2000-02-22 | 2000-02-22 | |
US60/184,053 | 2000-02-22 | ||
US09/552,172 US6258385B1 (en) | 1999-04-22 | 2000-04-18 | Tetrasilver tetroxide treatment for skin conditions |
US09/552,172 | 2000-04-18 | ||
US21450300P | 2000-06-28 | 2000-06-28 | |
US60/214,503 | 2000-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001049301A1 true WO2001049301A1 (en) | 2001-07-12 |
Family
ID=40458508
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/029115 WO2001049302A1 (en) | 2000-01-06 | 2000-10-20 | Compositions and methods for facilitating skin growth and managing skin conditions |
PCT/US2000/029116 WO2001049303A1 (en) | 2000-01-06 | 2000-10-20 | Multivalent electron active compositions and methods of making and using same |
PCT/US2000/029113 WO2001049301A1 (en) | 2000-01-06 | 2000-10-20 | Methods of using electron active compounds for managing cancer |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/029115 WO2001049302A1 (en) | 2000-01-06 | 2000-10-20 | Compositions and methods for facilitating skin growth and managing skin conditions |
PCT/US2000/029116 WO2001049303A1 (en) | 2000-01-06 | 2000-10-20 | Multivalent electron active compositions and methods of making and using same |
Country Status (8)
Country | Link |
---|---|
EP (3) | EP1246629A4 (en) |
JP (3) | JP2003519189A (en) |
AR (1) | AR029184A1 (en) |
AU (3) | AU784597B2 (en) |
CO (1) | CO5271678A1 (en) |
GT (1) | GT200000184A (en) |
TW (1) | TWI235661B (en) |
WO (3) | WO2001049302A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002085386A2 (en) * | 2001-04-23 | 2002-10-31 | Nucryst Pharmaceuticals Corp. | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
JP2006521384A (en) * | 2003-03-24 | 2006-09-21 | ウェルスタット バイオロジクス コーポレイション | Administration of Newcastle disease virus |
US8754133B2 (en) | 2001-11-02 | 2014-06-17 | Proteotech, Inc. | Compounds, compositions and methods for the treatment of inflammatory diseases |
US8865227B2 (en) | 2007-12-20 | 2014-10-21 | Smith & Nephew (Overseas) Limited | Metal carbonate particles and methods of making thereof |
US9066917B2 (en) | 2009-08-03 | 2015-06-30 | Cytochroma Development Inc. | Mixed metal compound |
US9168270B2 (en) | 2006-01-31 | 2015-10-27 | Opko Ireland Global Holdings, Ltd. | Water-insoluble, iron-containing mixed metal, granular material |
US9242869B2 (en) | 1997-09-19 | 2016-01-26 | Opko Ireland Global Holdings, Ltd. | Metal compounds mixed or sulphated, as phosphate binders |
US9566302B2 (en) | 2010-02-04 | 2017-02-14 | Opko Ireland Global Holdings, Ltd. | Composition comprising mixed metal compounds and xanthan gum |
US10155040B2 (en) | 2007-10-16 | 2018-12-18 | Opko Ireland Global Holdings, Ltd. | Mixed metal compounds for treatment of hyperphosphataemia |
US10201501B2 (en) | 2007-07-27 | 2019-02-12 | Opko Ireland Global Holdings, Ltd. | Mixed metal compounds used as antacids |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7635488B2 (en) | 2001-03-13 | 2009-12-22 | Dbv Technologies | Patches and uses thereof |
EP1369120B1 (en) * | 2002-06-03 | 2007-02-14 | National Health Research Institutes | Treatment of flavivirus infection |
US8048870B2 (en) * | 2005-01-11 | 2011-11-01 | Batarseh Kareem I | Apoptosis-inducing antineoplastic silver (I) coordination complexes |
SI2343304T1 (en) * | 2005-02-16 | 2015-08-31 | Anacor Pharmaceuticals, Inc. | Biocidal boronophthalide compounds |
EP1976536A4 (en) | 2005-12-30 | 2011-03-02 | Anacor Pharmaceuticals Inc | Boron-containing small molecules |
CN101420854B (en) | 2006-02-16 | 2013-08-07 | 安纳考尔医药公司 | Boron-containing small molecules as anti-inflammatory agents |
DE102006023394A1 (en) * | 2006-05-17 | 2007-11-22 | Gerd Prof. Wengler | Preparation and use of an antiviral chemotherapeutic agent which affects a host cell to block the replication of viruses in the cell |
FR2924350B1 (en) | 2007-12-03 | 2010-08-13 | Dbv Tech | METHOD AND COMPOSITIONS FOR SKIN VACCINATION |
FR2924349B1 (en) | 2007-12-03 | 2010-01-01 | Dbv Tech | ALLERGEN DISENSIBILITY METHOD |
RU2015109165A (en) | 2008-03-06 | 2015-11-10 | Анакор Фармасьютикалз, Инк. | WOODEN SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS |
JP5505679B2 (en) * | 2008-07-04 | 2014-05-28 | 和宏 小川 | Treatment or prevention of protozoan infections |
EP2348863A4 (en) | 2008-09-04 | 2012-03-07 | Anacor Pharmaceuticals Inc | Boron-containing small molecules |
US8461336B2 (en) | 2008-09-04 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
GB2472126B (en) * | 2009-07-21 | 2011-08-03 | Aidance Skincare & Topical Solutions Llc | Topical Formulations Containing Silver (II) Oxide and Zinc Oxide |
AP4039A (en) | 2009-08-14 | 2017-02-28 | Daitao Chen | Boron-containing small molecules as antiprotozoal agents |
US9346834B2 (en) | 2009-10-20 | 2016-05-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US8461134B2 (en) | 2009-11-11 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
JP5570006B2 (en) | 2009-12-24 | 2014-08-13 | 国立大学法人 東京大学 | Virus inactivating agent |
WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
AP2012006482A0 (en) | 2010-03-19 | 2012-10-31 | Anacor Pharmacueticals Inc | Boron-containing small molecules as anti-protozoalagent |
SG10201507032YA (en) | 2010-09-07 | 2015-10-29 | Anacor Pharmaceuticals Inc | Benzoxaborole derivatives for treating bacterial infections |
CN103338641B (en) * | 2010-12-22 | 2015-11-25 | 国立大学法人东京大学 | Via |
JP5824704B1 (en) * | 2014-07-20 | 2015-11-25 | 株式会社ライラック研究所 | Powder-like stagnation agent |
US11224227B2 (en) | 2015-02-08 | 2022-01-18 | Argaman Technologies Ltd. | Antimicrobial material comprising synergistic combinations of metal oxides |
WO2016125132A1 (en) | 2015-02-08 | 2016-08-11 | Argaman Technologies Ltd. | Antimicrobial material comprising synergistic combinations of metal oxides |
JP6775927B2 (en) * | 2015-08-27 | 2020-10-28 | 住化エンバイロメンタルサイエンス株式会社 | Antibacterial composition |
EP3269357A1 (en) * | 2016-07-15 | 2018-01-17 | Universiteit Gent | Particles comprising metals and/or metal oxides for use to transform compounds in vivo |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4574782A (en) * | 1981-11-16 | 1986-03-11 | Corning Glass Works | Radio frequency-induced hyperthermia for tumor therapy |
US4735796A (en) * | 1983-12-08 | 1988-04-05 | Gordon Robert T | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
US5928958A (en) * | 1994-07-27 | 1999-07-27 | Pilgrimm; Herbert | Superparamagnetic particles, process for their manufacture and usage |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2199459B1 (en) * | 1972-09-20 | 1975-08-08 | Agronomique Inst Nat Rech | |
FR2245351A2 (en) * | 1973-09-27 | 1975-04-25 | Agronomique Inst Nat Rech | Injectable trace element compns - as suspensions in oil for treating trace element deficiencies in animals |
DK313381A (en) * | 1980-07-24 | 1982-01-25 | Mckechnike Chemicals Ltd | REGULATED TRANSMISSION RELEASE |
US4994014A (en) * | 1988-07-26 | 1991-02-19 | Gordon Robert T | Process for treating diseased cells including the step of raising the subjects blood oxygen level |
US5612019A (en) * | 1988-12-19 | 1997-03-18 | Gordon, Deceased; David | Diagnosis and treatment of HIV viral infection using magnetic metal transferrin particles |
JPH0525051A (en) * | 1991-07-19 | 1993-02-02 | Meiji Seika Kaisha Ltd | Anemia-preventive/therapeutic agent |
US5336499A (en) * | 1992-01-10 | 1994-08-09 | Antelman Technologies, Ltd. | Molecular crystal device for pharmaceuticals |
US5676977A (en) * | 1994-09-22 | 1997-10-14 | Antelman Technologies Ltd. | Method of curing AIDS with tetrasilver tetroxide molecular crystal devices |
JPH0912415A (en) * | 1995-06-29 | 1997-01-14 | Sekisui Chem Co Ltd | Antibacterial composition and antibacterial and bactericidal treatment |
DE19600744A1 (en) * | 1996-01-11 | 1997-07-17 | Werner Alois Prof Dipl Kaiser | Magnetic substance for local hyperthermic treatment of mainly small tumors |
DE19624426A1 (en) * | 1996-06-19 | 1998-01-02 | Christian Bergemann | Magnetic particle for transport of diagnostic or therapeutic agent |
JPH10218779A (en) * | 1997-02-10 | 1998-08-18 | Nippon Electric Glass Co Ltd | Hyperthermic material |
DE19716732C2 (en) * | 1997-03-07 | 1999-03-25 | Max Delbrueck Centrum | Specific magnetosomes, processes for their preparation and their use |
JP2000060976A (en) * | 1998-08-21 | 2000-02-29 | Hiroaki Koyanagi | Skin contact body used in skin contact with effective spot and route contining to spot of human body |
-
2000
- 2000-10-20 WO PCT/US2000/029115 patent/WO2001049302A1/en active Search and Examination
- 2000-10-20 AU AU13396/01A patent/AU784597B2/en not_active Ceased
- 2000-10-20 EP EP00975330A patent/EP1246629A4/en not_active Withdrawn
- 2000-10-20 EP EP00976613A patent/EP1246630A4/en not_active Withdrawn
- 2000-10-20 AR ARP000105557A patent/AR029184A1/en unknown
- 2000-10-20 AU AU12222/01A patent/AU1222201A/en not_active Abandoned
- 2000-10-20 JP JP2001549671A patent/JP2003519189A/en active Pending
- 2000-10-20 WO PCT/US2000/029116 patent/WO2001049303A1/en not_active Application Discontinuation
- 2000-10-20 EP EP00973747A patent/EP1250142A4/en not_active Withdrawn
- 2000-10-20 CO CO00080126A patent/CO5271678A1/en unknown
- 2000-10-20 AU AU14359/01A patent/AU784593B2/en not_active Ceased
- 2000-10-20 JP JP2001549669A patent/JP2003519187A/en active Pending
- 2000-10-20 WO PCT/US2000/029113 patent/WO2001049301A1/en not_active Application Discontinuation
- 2000-10-20 JP JP2001549670A patent/JP2003519188A/en active Pending
- 2000-10-23 GT GT200000184A patent/GT200000184A/en unknown
- 2000-10-23 TW TW089122108A patent/TWI235661B/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4574782A (en) * | 1981-11-16 | 1986-03-11 | Corning Glass Works | Radio frequency-induced hyperthermia for tumor therapy |
US4735796A (en) * | 1983-12-08 | 1988-04-05 | Gordon Robert T | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
US5928958A (en) * | 1994-07-27 | 1999-07-27 | Pilgrimm; Herbert | Superparamagnetic particles, process for their manufacture and usage |
Non-Patent Citations (1)
Title |
---|
See also references of EP1246629A4 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9242869B2 (en) | 1997-09-19 | 2016-01-26 | Opko Ireland Global Holdings, Ltd. | Metal compounds mixed or sulphated, as phosphate binders |
WO2002085386A2 (en) * | 2001-04-23 | 2002-10-31 | Nucryst Pharmaceuticals Corp. | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
WO2002085386A3 (en) * | 2001-04-23 | 2003-01-16 | Nucryst Pharm Corp | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
US8754133B2 (en) | 2001-11-02 | 2014-06-17 | Proteotech, Inc. | Compounds, compositions and methods for the treatment of inflammatory diseases |
JP2006521384A (en) * | 2003-03-24 | 2006-09-21 | ウェルスタット バイオロジクス コーポレイション | Administration of Newcastle disease virus |
US9168270B2 (en) | 2006-01-31 | 2015-10-27 | Opko Ireland Global Holdings, Ltd. | Water-insoluble, iron-containing mixed metal, granular material |
US9907816B2 (en) | 2006-01-31 | 2018-03-06 | Opko Ireland Global Holdings, Ltd. | Water-insoluble, iron-containing mixed metal, granular material |
US10201501B2 (en) | 2007-07-27 | 2019-02-12 | Opko Ireland Global Holdings, Ltd. | Mixed metal compounds used as antacids |
US10155040B2 (en) | 2007-10-16 | 2018-12-18 | Opko Ireland Global Holdings, Ltd. | Mixed metal compounds for treatment of hyperphosphataemia |
US8865227B2 (en) | 2007-12-20 | 2014-10-21 | Smith & Nephew (Overseas) Limited | Metal carbonate particles and methods of making thereof |
US9066917B2 (en) | 2009-08-03 | 2015-06-30 | Cytochroma Development Inc. | Mixed metal compound |
US9314481B2 (en) | 2009-08-03 | 2016-04-19 | Opko Ireland Global Holdings, Ltd. | Method |
US9566302B2 (en) | 2010-02-04 | 2017-02-14 | Opko Ireland Global Holdings, Ltd. | Composition comprising mixed metal compounds and xanthan gum |
Also Published As
Publication number | Publication date |
---|---|
EP1246629A4 (en) | 2007-04-18 |
EP1250142A1 (en) | 2002-10-23 |
AU784593B2 (en) | 2006-05-11 |
AU1435901A (en) | 2001-07-16 |
CO5271678A1 (en) | 2003-04-30 |
AU784597B2 (en) | 2006-05-11 |
EP1246630A1 (en) | 2002-10-09 |
WO2001049302A1 (en) | 2001-07-12 |
EP1246630A4 (en) | 2007-04-18 |
JP2003519189A (en) | 2003-06-17 |
AU1222201A (en) | 2001-07-16 |
TWI235661B (en) | 2005-07-11 |
WO2001049303A1 (en) | 2001-07-12 |
JP2003519187A (en) | 2003-06-17 |
AU1339601A (en) | 2001-07-16 |
AR029184A1 (en) | 2003-06-18 |
EP1250142A4 (en) | 2007-07-11 |
EP1246629A1 (en) | 2002-10-09 |
GT200000184A (en) | 2002-04-16 |
JP2003519188A (en) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU784597B2 (en) | Methods of using electron active compounds for managing cancer | |
US6258385B1 (en) | Tetrasilver tetroxide treatment for skin conditions | |
Auchincloss et al. | Cancer of the breast possibly induced by estrogenic substance | |
US6669966B1 (en) | Compositions for facilitating skin growth and methods and articles using same | |
AU3133399A (en) | The use of polyamines in the treatment of dermatological symptoms | |
Smith et al. | Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma | |
Koh et al. | Dermatofibrosarcoma protuberans | |
US6485755B1 (en) | Methods of using electron active compounds for managing cancer | |
US8012954B2 (en) | Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions | |
US20060105057A1 (en) | Compositions using tetrasilver tetroxide and methods for management of skin conditions using same | |
CURTIS et al. | Use of two stilbene derivatives (diethylstilbestrol and stilbamidine) in treatment of blastomycosis | |
Ferrandina et al. | Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro | |
Patchefsky et al. | Psammoma bodies in diffuse toxic goiter | |
US20040022868A1 (en) | Compositions using tetrasilver tetroxide and methods for management of skin conditions using same | |
Marshall | Experimental Basis of Chemotherapy in the Treatment of Bacterial Infections: The Ludwig Kast Lecture | |
KR20200015549A (en) | Use of Coenzyme Q10 Formulations in the Treatment and Prevention of Bullous Epidermolysis | |
RU2139060C1 (en) | Complex biologically active preparation | |
WO2023249591A1 (en) | An encapsulated pharmaceutical compound for treating drymouth and symptoms caused by systemic diseases | |
US10894032B2 (en) | Microbial-relief composition | |
JPH043363B2 (en) | ||
PECK et al. | Aqueous solutions of sodium propionate with chlorophyll as a therapeutic agent | |
Healy | Report of a case of intractable vulvar ulcer (esthiomene) cured by proteus vaccines | |
Fordham et al. | CAsE stUDy 1–8. UlCErAtED HEMANgIoMAs | |
Lafferty et al. | One and One-half Years' Experience in the Employment of 220 Kilovolts X-ray Therapy with Heavy Filter: Report on Seven Cases of Carcinoma of the Bladder | |
Wieder et al. | CHICAGO DERMATOLOGICAL SOCIETY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 13396/01 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 549669 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000975330 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000975330 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000975330 Country of ref document: EP |